PubMed Health⌕ Search

Biomedical subjects

J Boccio

Publications and source records attributed to J Boccio.

23 records · Page 2Linked to original sources

MIN 14C UBT: a combination of gastric basal transit and 14C-urea breath test for the detection of Helicobacter pylori infection in human beings.

The purpose of this work is to demonstrate that the 14C-urea breath test (UBT) performed at different times combined with the study of the gastric basal transit, which evaluates the intragastric displacement of a labeled solution under fasting conditions, has the advantage of being representative of the whole stomach surface and constitutes a non-aggressive test for the detection of H. pylori. This test, which has been called MIN 14C UBT, is a modification of the conventional 14C UBT in which low volumes of a solution of 14C-urea together with 99mTc-sulfur colloid are administered. The 99mTc-sulfur colloid is not absorbed in the gastrointestinal tract and has the great advantage of allowing the "visualization" of the transit of the 14C-urea within the gastrointestinal tract. This modification allows the simultaneous determination of the production of the 14CO2 and the place where this process occurs. The results show that there is a good correlation between the images obtained and the breath samples collected. We found that this test has a sensitivity of 98% and a specificity of 96% for H. pylori detection.

Breath Tests↗

[Brachytherapy of solid tumors. Use of chromic phosphate colloid].

With the purpose of studying the effectivity of an intratumoral single dose of chromic [32P] phosphate (Phosphocol) for the treatment of solid tumors, studies of bioelimination, biodistribution and therapeutic action were carried out in rats with experimental induced tumors. The results show that the percentage of total elimination is equal to 29.76 +/- 9.60% with a higher percentage in faeces 23.28 +/- 8.81% than in urine 6.48 +/- 2.11%. Biodistribution studies show that, 51.61 +/- 5.82% of the injected activity is found in the tumor while in organs with reticuloendothelial cells, the percentage of activity was 13.09 +/- 5.15% in liver and 2.88 +/- 1.23% in lung. On the other hand, when therapeutic action was evaluated, we found that the percentage of tumor regression (P.T.R) was 61.0% for the injected tumors. It is important to point out that 4 of the treated animals show bioelimination patterns in which the elimination rises suddenly at some time of the study. These results demonstrate that the use of this kind of colloids is not to be recommended for the treatment of solid tumors with moderated degree of vascularization, since its mobilization from the injection point may result in the consequent irradiation of different organs that are not under treatment.

Adenocarcinoma↗

"In vivo" and "in vitro" antitumoral action of Larrea divaricata Cav.

We previously reported that aqueous extract of Larrea divaricata Cav. had an antiproliferative activity upon tumoral lymphoid cells (BW 5147), without affecting normal immunity. To determine the probable mechanism of the inhibitory action of the extract upon cell growth, the participation of intracellular signals involved in the inhibition of cell proliferation, namely the activation of adenylate cyclase system was studied. The production of cyclic 3', 5 adenosine monophosphate (cAMP) in presence and absence of extract was analized. The extract increased the cAMP levels, but neither the cAMP production nor the inhibitory effect of the extract on proliferation were blocked by a beta adrenergic receptor antagonist (propranolol) or by histaminergic receptor antagonists (cimetidine and mepyramine). So, we concluded that the antiproliferative activity of the extract of BW 5147 cells would be mediated by an increase in cAMP intracellular levels no related to the activation of the membrane receptors here studied. In parallel, the extract was administered to a pregnant rat with a spontaneous mammarian carcinoma and "in vivo" antitumoral activity was found.

Analysis of Variance↗